Literature DB >> 31800294

Cost of Treating Skin Problems in Patients with Diabetes Who Use Insulin Pumps and/or Glucose Sensors.

Anna Korsgaard Berg1,2, Steffen Ullitz Thorsen1, Jacob P Thyssen3, Claus Zachariae3, Hans Keiding4, Jannet Svensson1,2.   

Abstract

Background: The use of insulin pump and glucose sensor is advantageous, but unfortunately many experience skin problems. To reduce or overcome skin problems, patients use additional products or change their sets preterm. Therefore, the aim was to investigate costs related to skin problems. Materials and
Methods: Two hundred sixty-three patients from four different hospitals in Denmark participated in a cross-sectional survey about skin problems related to insulin pump and/or glucose sensor use. Additional costs aside technology and diabetes treatment were calculated based on adhesives, patches, lotion, and preterm shifts of infusion or sensor sets due to skin problems. Descriptive statistics and linear regression were used.
Results: The total costs for all these expenses were 11493.9 U.S. dollars (USD) in 145 pediatric patients and 4843 USD in 118 adult patients. The costs were higher in patients with, than without, skin problems and for skin problems due to the glucose sensor compared with insulin pump. Pediatric patients with eczema and/or wound due to the glucose sensor did cost 154.3 USD more, than patients without these skin problems (P < 0.01). We found a clear dose/response relationship between costs and severity of skin problems, especially in pediatric patients. Conclusions: Our data show that skin problems due to use of insulin pump and/or glucose sensor have significant costs on the Danish welfare system. This leaves an economic incentive for developing more skin-sensitive adhesive for the infusion set and sensors, at least for a certain subgroup of patients.

Entities:  

Keywords:  Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Dermatology; Pediatric; Type 1 diabetes

Year:  2020        PMID: 31800294     DOI: 10.1089/dia.2019.0368

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  4 in total

1.  Insulin Pump-related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes.

Authors:  Estelle M Everett; Timothy P Copeland; Tannaz Moin; Lauren E Wisk
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 2.  Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices.

Authors:  A Herman; W Uter; T Rustemeyer; M Matura; K Aalto-Korte; J Duus Johansen; M Gonçalo; I R White; A Balato; A M Giménez Arnau; K Brockow; C G Mortz; V Mahler; A Goossens
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-06       Impact factor: 6.166

3.  Nanoplasmonic Strip Test for Salivary Glucose Monitoring.

Authors:  Helena Torné-Morató; Paolo Donati; Pier Paolo Pompa
Journal:  Nanomaterials (Basel)       Date:  2021-12-29       Impact factor: 5.076

Review 4.  The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes.

Authors:  Ryota Inoue; Kuniyuki Nishiyama; Jinghe Li; Daisuke Miyashita; Masato Ono; Yasuo Terauchi; Jun Shirakawa
Journal:  Cells       Date:  2021-06-24       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.